Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC). Survival of patients (pts) ...

The most common symptoms for colorectal cancer in younger patients are abdominal pain; unexplained weight loss; changes in the frequency, size or appearance of stools; and rectal bleeding ...

Mortality and morbidity outcomes in patients with inflammatory bowel disease with colon cancer: A nationwide analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.